112 related articles for article (PubMed ID: 12840798)
21. Erlotinib: as maintenance monotherapy in non-small-cell lung cancer.
Muir VJ; Dhillon S
BioDrugs; 2011 Jun; 25(3):139-46. PubMed ID: 21513367
[TBL] [Abstract][Full Text] [Related]
22. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.
Hilton JF; Tu D; Seymour L; Shepherd FA; Bradbury PA
Lung Cancer; 2013 Oct; 82(1):136-42. PubMed ID: 23910908
[TBL] [Abstract][Full Text] [Related]
23. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
Schaefer G; Shao L; Totpal K; Akita RW
Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
[TBL] [Abstract][Full Text] [Related]
24. A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
Iyer R; Bharthuar A
Expert Opin Pharmacother; 2010 Feb; 11(2):311-20. PubMed ID: 20088749
[TBL] [Abstract][Full Text] [Related]
25. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
Davies AM; Ho C; Beckett L; Lau D; Scudder SA; Lara PN; Perkins N; Gandara DR
J Thorac Oncol; 2009 Jul; 4(7):862-8. PubMed ID: 19494788
[TBL] [Abstract][Full Text] [Related]
26. Erlotinib OSI/Roche/Genentech.
Kim TE; Murren JR
Curr Opin Investig Drugs; 2002 Sep; 3(9):1385-95. PubMed ID: 12498017
[TBL] [Abstract][Full Text] [Related]
27. Identifying predictive and surrogate markers of erlotinib antitumor activity other than rash.
Soulières D
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):29-33. PubMed ID: 14682121
[TBL] [Abstract][Full Text] [Related]
28. Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
Welch SA; Moore MJ
Future Oncol; 2007 Jun; 3(3):247-54. PubMed ID: 17547518
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
[TBL] [Abstract][Full Text] [Related]
30. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.
Friess T; Scheuer W; Hasmann M
Anticancer Res; 2006; 26(5A):3505-12. PubMed ID: 17094474
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
[TBL] [Abstract][Full Text] [Related]
32. Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer.
Sutter AP; Höpfner M; Huether A; Maaser K; Scherübl H
Int J Cancer; 2006 Apr; 118(7):1814-22. PubMed ID: 16217753
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Tan AR; Yang X; Hewitt SM; Berman A; Lepper ER; Sparreboom A; Parr AL; Figg WD; Chow C; Steinberg SM; Bacharach SL; Whatley M; Carrasquillo JA; Brahim JS; Ettenberg SA; Lipkowitz S; Swain SM
J Clin Oncol; 2004 Aug; 22(15):3080-90. PubMed ID: 15284258
[TBL] [Abstract][Full Text] [Related]
34. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
35. Chronopharmacodynamics and mechanisms of antitumor effect induced by erlotinib in xenograft-bearing nude mice.
Lin P; An F; Xu X; Zhao L; Liu L; Liu N; Wang P; Liu J; Wang L; Li M
Biochem Biophys Res Commun; 2015 May; 460(2):362-7. PubMed ID: 25791480
[TBL] [Abstract][Full Text] [Related]
36. Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
Petit-Jean E; Buclin T; Guidi M; Quoix E; Gourieux B; Decosterd LA; Gairard-Dory AC; Ubeaud-Séquier G; Widmer N
Ther Drug Monit; 2015 Feb; 37(1):2-21. PubMed ID: 24831652
[TBL] [Abstract][Full Text] [Related]
37. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
38. FDA drug approval summary: erlotinib (Tarceva) tablets.
Cohen MH; Johnson JR; Chen YF; Sridhara R; Pazdur R
Oncologist; 2005 Aug; 10(7):461-6. PubMed ID: 16079312
[TBL] [Abstract][Full Text] [Related]
39. The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.
Suda K; Mizuuchi H; Sato K; Takemoto T; Iwasaki T; Mitsudomi T
Int J Cancer; 2014 Aug; 135(4):1002-6. PubMed ID: 24458568
[TBL] [Abstract][Full Text] [Related]
40. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
Agulnik M; da Cunha Santos G; Hedley D; Nicklee T; Dos Reis PP; Ho J; Pond GR; Chen H; Chen S; Shyr Y; Winquist E; Soulieres D; Chen EX; Squire JA; Marrano P; Kamel-Reid S; Dancey J; Siu LL; Tsao MS
J Clin Oncol; 2007 Jun; 25(16):2184-90. PubMed ID: 17538163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
